✓ Translated by DotMD AI Clinical Council Source: Hepatology (Baltimore, Md.) • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #39808820 ↗

Phase III Randomized Trial: Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection (N = 332)

Original Paper Title: “Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 332
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Postoperative adjuvant TACE was not associated with prolonged RFS or overall survival in patients with American Joint Committee on Cancer TNM stage I or II HCC.
  • Study Design & Sample: Phase III Randomized Trial published in Hepatology (Baltimore, Md.) (N = 332 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Hepatology (Baltimore, Md.) (2025), this phase iii randomized trial evaluating 332 human participants investigated: The role of adjuvant transarterial chemoembolization (TACE) for HCC following curative resection remains controversial. Key clinical takeaway: Postoperative adjuvant TACE was not associated with prolonged RFS or overall survival in patients with American Joint Committee on Cancer TNM stage I or II HCC.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Hepatology (Baltimore, Md.), 2025-11-01; N = 332; Rigor 87/100): Postoperative adjuvant TACE was not associated with prolonged RFS or overall survival in patients with American Joint Committee on Cancer TNM stage I or II HCC.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: malignant-neoplasm-of-lower-lobe-unspecified-bronchus-or-lung → Condition: malignant-neoplasm-of-lower-lobe-right-bronchus-or-lung →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39808820: Phase III Randomized Trial: Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection (N = 332)

3 of 3 Free Questions Remaining